Longhorn Vaccines And Diagnostics, Llc

Longhorn Vaccines and Diagnostics, LLC has been granted 29 US utility patents between 2015 and 2025, placing Longhorn Vaccines and Diagnostics, LLC at rank #10,671 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 28.2 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Longhorn Vaccines and Diagnostics, LLC is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 40.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 12 grants, compared with 17 in the 2015–2019 window, a -29% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Longhorn Vaccines and Diagnostics, LLC's 28.2 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Longhorn Vaccines and Diagnostics, LLC against peers pursuing similar technology classes.